1. Relapse

    Comments Leave a Comment

    1-15 of 73 1 2 3 4 5 »
    1. Mentioned In 73 Articles

    2. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

      PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
      ...Institute, Amsterdam, the Netherlands. The majority of high-risk neuroblastoma patients are refractory to, or relapse on, current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes t...
      Read Full Article
    3. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      ...o identify novel therapeutic targets. The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes th...
      Read Full Article
    4. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      ...re needed to improve these outcomes. Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes. Ponatinib is a...
      Read Full Article
      Mentions: Treatment Relapse
    5. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy
      ...to three years. “Leukemia cells evolve in order to find ways to survive,” said Summers. “For the patients who relapse with CD22-positive leukemia, we are very pleased to now be able to offer a treatment option that will ...
      Read Full Article
    6. Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

      Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults
      ...to three years. "Leukemia cells evolve in order to find ways to survive," said Summers. "For the patients who relapse with CD22-positive leukemia, we are very pleased to now be able to offer a treatment option that will ...
      Read Full Article
    7. 1-15 of 73 1 2 3 4 5 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Relapse

    1. Although current treatments improve survival rates, patients suffer severe side effects and relapse tumors carry mutations that resist treatment.
      In Study Suggests Repurposing Anti-depressant Medication to Target Medulloblastoma
    2. We've been able to identify groups of patients who we consider very low risk for relapse and have been able to pull back on their therapy and prevent over treating.
      In The Medical Minute: Research Continues Improving Odds for Kids with Cancer
    3. Recent studies suggest that epigenetic modifications may contribute to the development of cancer progenitor cells that can induce drug resistance and the relapse of different types of cancer.
      In Cancer resistance may one day be treated with epigenetic drugs